Wednesday, February 15, 2017 1:03:07 PM
The final and complete analyses, including the clinical study report, are expected to be completed in July 2016
The final and complete analyses, including the clinical study report, are expected to be completed in October 2016.
The final and complete analyses, including the clinical study report, are expected to be completed in December 2016.
The final and complete analyses, including the clinical study report, are expected to be completed during the first quarter of 2017
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM